The FDA approved Darzalex Faspro with VRd for newly diagnosed multiple myeloma patients ineligible for ASCT, based on the CEPHEUS trial results. The CEPHEUS trial showed improved MRD negativity rates ...

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new results from the Phase 1b/2 EPCORE ® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Antonia Haynes is a Game Rant writer who resides in a small seaside town in England where she has lived her whole life. Beginning her video game writing career in 2014, and having an avid love of ...

Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant (ASCT) for patients with mantle cell lymphoma (MCL) in remission following ...

It is the first evidence that MCL patients in complete remission, with undetectable minimal residual disease (MRD), may be able to rely on highly effective standard treatments and avoid the rigors of ...

There was no significant difference in failure-free survival between the ibrutinib arm and the transplant-ibrutinib arm. Ibrutinib-containing regimens may be the “preferred” first-line treatment for ...

Autologous stem cell transplantation (ASCT) shows improved DFS and RFS compared to chemotherapy in AML patients achieving complete response. ASCT is associated with a 50% reduction in relapse risk ...

Callum is a seasoned gaming managing editor for a number of publications and a gamer who will always try to shine a spotlight on indie games before giving AAA titles the time of day. He loves nothing ...

To continue the response they experienced with a first autologous stem‐cell transplant (ASCT) for their multiple myeloma, patients in this analysis received a second ASCT, with French investigators ...

Between June 2015 and June 2017, 90 patients were included, and 31% met at least one SixtyLightchain MRI (SLiM)-hypercalcemia, renal impairment, anemia, bone disease (CRAB) criterion. After a median ...